• Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells 

      Starheim, Kristian Kobbenes; Holien, Toril; Misund, Kristine; Johansson, Ida; Baranowska, Katarzyna Anna; Sponaas, Anne Marit; Hella, Hanne; Buene, Glenn; Waage, Anders; Sundan, Anders; Bjørkøy, Geir (Journal article; Peer reviewed, 2016)
      Multiple myeloma (myeloma in short) is an incurable cancer of antibody-producing plasma cells that comprise 13% of all hematological malignancies. The proteasome inhibitor bortezomib has improved treatment significantly, ...
    • Multiple Myeloma-study of cellular sensitivity to proteasome inhibitors 

      Baranowska, Katarzyna Anna (Doctoral theses at NTNU;2018:273, Doctoral thesis, 2018)
      Myelomatose (benmargskreft) – en studie av kreftcellenes følsomhet for kreftmedisiner i gruppen proteasomhemmere Myelomatose er en kreftform som utvikler seg i beinmargen og karakteriseres av ukontrollert vekst av de ...
    • MYC amplifications in myeloma cell lines; correlation with MYC-inhibitor efficacy 

      Holien, Toril; Misund, Kristine; Olsen, Oddrun Elise; Baranowska, Katarzyna Anna; Buene, Glenn; Børset, Magne; Waage, Anders; Sundan, Anders (Journal article; Peer reviewed, 2015)
      In multiple myeloma, elevated MYC expression is related to disease initiation and progression. We found that in myeloma cell lines, MYC gene amplifications were common and correlated with MYC mRNA and protein. In primary ...